Private Advisor Group LLC purchased a new stake in shares of Zafgen Inc (NASDAQ:ZFGN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 16,000 shares of the biopharmaceutical company’s stock, valued at approximately $153,000. Private Advisor Group LLC owned 0.06% of Zafgen as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Zafgen during the 2nd quarter worth $110,000. Trexquant Investment LP purchased a new stake in shares of Zafgen during the 2nd quarter worth $117,000. Barclays PLC lifted its position in shares of Zafgen by 139,086.7% during the 1st quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 20,863 shares during the last quarter. A.R.T. Advisors LLC lifted its position in shares of Zafgen by 62.9% during the 1st quarter. A.R.T. Advisors LLC now owns 23,053 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 8,904 shares during the last quarter. Finally, Element Capital Management LLC purchased a new stake in shares of Zafgen during the 1st quarter worth $174,000. Hedge funds and other institutional investors own 72.58% of the company’s stock.
Shares of NASDAQ:ZFGN opened at $10.14 on Tuesday. Zafgen Inc has a one year low of $3.37 and a one year high of $12.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 8.42 and a quick ratio of 8.42. The stock has a market capitalization of $430.25 million, a PE ratio of -5.34 and a beta of -0.64.
Several research firms have recently issued reports on ZFGN. BidaskClub raised shares of Zafgen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 27th. Wedbush initiated coverage on shares of Zafgen in a research report on Thursday, August 2nd. They issued an “outperform” rating and a $14.00 price target for the company. Zacks Investment Research raised shares of Zafgen from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. Piper Jaffray Companies initiated coverage on shares of Zafgen in a research report on Tuesday, July 3rd. They issued an “overweight” rating and a $18.00 price target for the company. Finally, ValuEngine raised shares of Zafgen from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $15.25.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.